Nipride RTU
Nipride RTU (Sodium Nitroprusside) is a rapid-acting, direct-acting vasodilator that dilates both peripheral arteries and veins. It is administered via continuous intravenous infusion to immediately lower blood pressure in hypertensive emergencies and to reduce preload and afterload in severe heart failure.
Dosage by Body Weight
Must be administered via an infusion pump to allow precise flow rate control. The standard starting infusion rate for both pediatric and adult patients is 0.3 mcg/kg/min, titrated upward gradually every few minutes to achieve the desired hemodynamic effect. Do not exceed the maximum infusion rate of 10 mcg/kg/min to avoid cyanide toxicity.
- Body Weight
- Below 5 kg
- Dose
- 0.3 mcg/kg/min (Starting dose: ~1.5 mcg/min or less)
- Frequency
- Continuous IV infusion
- Tracking Notes
- Extremely sensitive population. Continuous invasive arterial blood pressure monitoring is mandatory. Limit duration to avoid cyanide accumulation.
- Body Weight
- 5-7 kg
- Dose
- 0.3 mcg/kg/min (Starting dose: 1.5 to 2.1 mcg/min)
- Frequency
- Continuous IV infusion
- Tracking Notes
- Titrate carefully to clinical endpoint. Monitor acid-base status and venous oxygen saturation as indicators of toxicity.
- Body Weight
- 8-10 kg
- Dose
- 0.3 mcg/kg/min (Starting dose: 2.4 to 3.0 mcg/min)
- Frequency
- Continuous IV infusion
- Tracking Notes
- Adjust infusion rate based on real-time blood pressure response. Do not administer at maximum rate (10 mcg/kg/min) for more than 10 minutes.
- Body Weight
- 11-15 kg
- Dose
- 0.3 mcg/kg/min (Starting dose: 3.3 to 4.5 mcg/min)
- Frequency
- Continuous IV infusion
- Tracking Notes
- Ensure adequate renal and hepatic function. Consider co-administration of sodium thiosulfate if prolonged infusion is necessary.
- Body Weight
- 16-20 kg
- Dose
- 0.3 mcg/kg/min (Starting dose: 4.8 to 6.0 mcg/min)
- Frequency
- Continuous IV infusion
- Tracking Notes
- Monitor for signs of thiocyanate/cyanide toxicity (e.g., metabolic acidosis, altered mental status) during prolonged use.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | 0.3 mcg/kg/min (Starting dose: ~1.5 mcg/min or less) | Continuous IV infusion | Extremely sensitive population. Continuous invasive arterial blood pressure monitoring is mandatory. Limit duration to avoid cyanide accumulation. |
| 5-7 kg | 0.3 mcg/kg/min (Starting dose: 1.5 to 2.1 mcg/min) | Continuous IV infusion | Titrate carefully to clinical endpoint. Monitor acid-base status and venous oxygen saturation as indicators of toxicity. |
| 8-10 kg | 0.3 mcg/kg/min (Starting dose: 2.4 to 3.0 mcg/min) | Continuous IV infusion | Adjust infusion rate based on real-time blood pressure response. Do not administer at maximum rate (10 mcg/kg/min) for more than 10 minutes. |
| 11-15 kg | 0.3 mcg/kg/min (Starting dose: 3.3 to 4.5 mcg/min) | Continuous IV infusion | Ensure adequate renal and hepatic function. Consider co-administration of sodium thiosulfate if prolonged infusion is necessary. |
| 16-20 kg | 0.3 mcg/kg/min (Starting dose: 4.8 to 6.0 mcg/min) | Continuous IV infusion | Monitor for signs of thiocyanate/cyanide toxicity (e.g., metabolic acidosis, altered mental status) during prolonged use. |
Formulation
Purpose
Immediate reduction of blood pressure in adult and pediatric patients with hypertensive crises; reduction of bleeding during surgery through controlled hypotension; treatment of acute congestive heart failure.
Generic Name
Sodium NitroprussideScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.